Verastem (VSTM) 2025 Update / Briefing June 02, 2025 12:00 PM ET Speaker0 Thanks everybody for coming. Very excited You're familiar with our story. We're really focused on RAFmAbK driven cancers. Within our own portfolio, we've got the RAFmec inhibitor of vutametinib, defactinib, which is our FAC inhibitor and then the G12D inhibitor. In addition to that, we do have two other targets as part of our Genfleet collaboration that we haven't disclosed. And so both within our own portfolio and then combining with ...

PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA. Details of the presentation are as follows: Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic WindowSes ...

文章核心观点 公司管理层在虚拟投资者环节讨论SON - 1010的积极安全结果及项目下一步计划 [1][2] 分组1：公司活动 - 公司管理层参与虚拟投资者“这意味着什么”环节 [1] - 临时首席执行官Raghu Rao和首席医疗官Richard Kenney博士讨论SON - 1010最高剂量与阿替利珠单抗联用的积极安全结果并介绍项目下一步计划 [2] - 该环节视频已发布 [3] 分组2：公司介绍 - 公司是专注肿瘤学的生物技术公司，拥有开发单功能或双功能靶向生物药物的FHAB平台 [4] - FHAB技术利用与人血清白蛋白结合的全人单链抗体片段运输到靶组织，可改善免疫调节生物药物的安全性和有效性 [4] - FHAB平台是增强多种大分子治疗药物的模块化、即插即用结构的基础 [4] 分组3：公司项目 - 公司主要项目SON - 1010正与罗氏合作评估，用于治疗铂耐药卵巢癌 [5] - 公司还在与肉瘤肿瘤中心合作评估使用该平台的第二个项目SON - 1210，用于治疗胰腺癌 [5]